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Certain skin disorders, such as contact dermatitis and chronic urticaria, are characterized by inﬂammation in-
volving mast cells and worsen by stress. The underlying mechanism of this effect, however, is not known. The skin
appears to have the equivalent of a hypothalamic–pituitary–adrenal (HPA) axis, including local expression of
corticotropin-releasing hormone (CRH) and its receptors (CRH-R). We have reported that acute stress and intra-
dermal administration of CRH stimulate skin mast cells and increase vascular permeability through CRH-R1 ac-
tivation. In this study, we investigated the expression of CRH-R1, the main CRH-R subtype in human skin, and the
mast cell related gene histidine decarboxylase (HDC), which regulates the production of histamine, in normal and
pathological skin biopsies. Quantitative real time PCR revealed that chronic urticaria expresses high levels of CRH-
R1 and HDC as compared to normal foreskin, breast skin and cultured human keratinocytes. The lichen simplex
samples had high expression of CRH-R1, but low HDC. These results implicate CRH-R in chronic urticaria, which is
often exacerbated by stress.
Key words: inflammation/mast cells/PCR/stress/urticaria
J Invest Dermatol 125:952 –955, 2005
Certain skin disorders, such as contact dermatitis, chronic
urticaria and psoriasis, are characterized by inflammation
and mast cell activation (Maurer et al, 2003), they are also
reportedly triggered or exacerbated by stress (Katsarou-
Katsari et al, 1999), but the mechanism remains unknown.
These conditions are associated with itch that involves his-
tamine and possibly other triggers/mediators.
Corticotropin-releasing hormone (CRH) and CRH recep-
tor (CRH-R) gene expression has been documented in ro-
dent and human skin (Slominski et al, 2001), which has been
proposed to have the equivalent of the hypothalamic–pitu-
itary–adrenal (HPA) axis (Slominski et al, 2000a). CRH in
mice is, however, released from nerve endings (Slominski
et al, 2001), whereas in humans it is synthesized by skin
cells (Slominski et al, 1998). The contribution of CRH to
cutaneous inflammatory processes has generated signifi-
cant interest, but had not been shown to be overexpressed
in any inflammatory skin disease so far. CRH regulates HPA
axis (Chrousos, 1995) through activation of CRH receptor-1
(CRH-R1), but both CRH-R1 and CRH-R2 have been also
identified outside the brain. CRH, itself, is also found out-
side the brain (Chalmers et al, 1996) and has been postu-
lated to have pro-inflammatory actions. CRH can be
synthesized by a variety of immune cells (Chrousos, 1995;
Karalis et al, 1997). Human mast cells, were recently shown
to be particularly rich in both CRH and the structurally re-
lated peptide Urocortin (Ucn), both of which could be se-
creted in response to immunologic stimulation (Kempuraj
et al, 2004). These stress peptides could, therefore, have
autocrine effects.
CRH and CRH-R expression in skin is associated with
the hair cycle (Roloff et al, 1998). Skin mast cells are jux-
taposed to nerve endings during hair follicle formation and
are located close to CRH-positive nerve endings (Rozniecki
et al, 1999), suggesting that they could have functional as-
sociations. We hypothesized that skin inflammatory disor-
ders exacerbated by stress may be characterized by
increased numbers of skin CRH-R and mast cells, so that
activation of CRH-R by stress peptides would lead to in-
creased mast cell stimulation and inflammation.
Here we studied the expression of CRH-R1 and histidine
decarboxylase (HDC), as a marker of mast cells, in skin from
controls and from patients with chronic urticaria.
Results
The characteristics of the samples used are presented in
Table I. Controls included normal foreskin from a male infant,
unaffected breast skin from a mastectomy and HaCaT hu-
man keratinocytes. There was also unaffected skin from one
post-menopausal female with poikiloderma of undetermined
Abbreviations: CRH, corticotropin-releasing hormone; HDC, histi-
dine decarboxylase; HPA, hypothalamic–pituitary–adrenal; Ucn,
urocortin
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etiology. There was one pre-menopausal female, one post-
hysterectomy female, as well as one male with chronic
urticaria (Table I). These patients reported that their symp-
toms worsened with emotional stress. One post-menopau-
sal female and one male with lichen simplex were also
included. Obviously, the patients from whom the biopsies
were obtained were not matched for sex or age and it is
difficult to make any direct comparisons. Unfortunately,
there was not sufficient biopsy material for both quantitative
PCR and immunohistochemistry.
There was low expression of CRH-R1 mRNA in normal
foreskin and it was used to compare expression in all other
samples. There was about 4-fold induction of CRH-R1
mRNA expression in human cultured keratinocytes
(4.1  0.6) and in unaffected skin from the patient with po-
ikiloderma (3.8  0.4) used as additional ‘‘controls’’, how-
ever, these results were not statistically significant (Fig 1). In
normal breast skin there was 7.85  0.016-fold increase in
CRH-R1 mRNA expression compared to foreskin. CRH-R1
mRNA expression was increased 24.6  0.9 fold in the fe-
male and 11  0.2 fold in (po0.001) the male with lichen
simplex. The expression was 17.9  0.4-fold higher in one
patient with chronic urticaria, whereas the second one had
18.7  0.2 (po0.01) fold increase and the third one had
12.7  0.0008-fold increase (n¼ 3, po0.01).
HDC mRNA expression was very low in the normal hu-
man foreskin and normal breast skin (1.84  0.05-fold) and
was absent in HaCaT human keratinocytes. It was about
8.3  0.1-fold higher in unaffected skin from the patient with
poikiloderma (po0.01) and 5.18 fold in the female with
lichen simplex, whereas it was 1.9-fold in the male with
lichen simplex (po0.01). HDC mRNA expression was,
however, 59.5  0.5-fold higher (po0.001) in one patient
with chronic urticaria,19.8  0.7-fold po0.01 in the other
and 9.76  0.09-fold in the third one as compared to normal
foreskin (n¼ 3, po0.001).
Discussion
CRH-R1 mRNA is shown to be overexpressed in any human
inflammatory skin disorder. Human skin, squamous cell
carcinoma and melanoma cells had been previously report-
ed to express CRH and CRH-R1 (Slominski et al, 1998;
Slominski et al, 2001). Normal foreskin had low expression
as did unaffected skin from a patient with poikiloderma of
unknown etiology and normal breast tissue. It is obvious
that this latter sample is not a healthytrue control because
there may be some systemic immunologic abnormality even
though none was uncovered. The biopsies showing the
highest expression of CRH-R1 and HDC were obtained
from patients who reported that their symptoms worsened
by stress. The lichen simplex biopsies did show increased
CRH-R1 mRNA expression, which may not be surprising
given the fact that it has been associated with higher levels
of stress (Chaudhary, 2004). Unfortunately, there was not
sufficient biopsy material to perform immunocytochemistry
for CRH-R1 protein. CRH-R1 overexpression in chronic ur-
tucaria may derive from keratinocytes, where it was orig-
inally described (Slominski et al, 2000b). Alternatively, skin
mast cells may, themselves, express CRH-Rs since normal
umbilical cord-derived human mast cells express mRNA
and protein for CRH-R1 (Cao et al, 2005).
Acute restraint stress was shown to induce increased
skin vascular permeability; (Singh et al, 1999) this effect was
mimicked by CRH, was inhibited by a CRH-R receptor
antagonist and was absent in mast cell deficient mice (The-
oharides et al, 1998). CRH-R1 was also involved in stress-
induced exacerbation of chronic contact dermatitis in rats
(Kaneko et al, 2003). CRH increased vascular permeability
in human skin shown by micro-iontophoresis, an effect de-
pendent on CRH-R1 and mast cells (Crompton et al, 2003).
Many dermatoses, such as chronic urticaria, contact
dermatitis and psoriasis, are reportedly triggered or exac-
erbated by stress (Katsarou-Katsari et al, 1999). Eczema
and acne, have also been reported to worsen by examina-
tion stress (Chiu et al, 2003). Chronic urticaria involves skin
inflammation mast cell activation and TH1 processes; how-
ever, its pathogenesis, especially the reason they are ex-
acerbated by stress, is not clear. Chronic urticaria may
involve sensitivity to foods, temperature, drugs and possible
autoimmune processes.
Chronic stress typically attenuates immune processes,
whereas acute stress appears to enhance antigen-specific
Table I. Characteristics of different human skin samples used for real-time quantitative PCR
Sample # Age (y) Sex Clinical conditiona Pre-menopausal Post-menopausal
1 1 Male Normal foreskin N/A N/A
2 42 Female Breast skin N/A N/A
3 72 Female Unaffected skin from poikiloderma  þ
4 60 Female Lichen simplex—A  þ
5 45 Male Lichen simplex—B N/A N/A
6 34 Female Chronic urticaria—A þ 
7 44 Female Chronic urticaria—B  þ b
8 42 Male Chronic urticaria—C N/A N/A
9 N/A N/A Human keratinocyte cell line N/A N/A
aSamples were obtained from patients who had not received any medication for 15 days prior to biopsy.
bPost-hysterectomy.
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cell-mediated immunity and causes a significant decrease
in circulating lymphocytes and monocytes with a shift to the
skin (Dhabhar and McEwen, 1999). It was further recently
shown that acute stress induces local release of CRH in the
skin (Lytinas et al, 2003).
Mast cells derive from stem cells in the bone marrow and
are prominently located just below the dermal–epidermal
junction; they mature under the influence of stem cell factor
(SCF), IL-3, IL-4 and IL-9 and are involved in allergic reac-
tions, but also in innate immunity (Maurer et al, 2003) and
inflammation (Theoharides and Cochrane, 2004). The in-
creased expression of HDC we report indicates either in-
creased mast cell enzyme activity or mast cell accumulation
(Conti et al, 1998). Mast cell infiltration and/or proliferation
may be triggered by SCF and by nerve growth factor (NGF),
which are also secreted from mast cells, as well as by
RANTES released from other immune cells (Conti et al,
1998). Histamine was recently shown to induce secretion of
NGF from normal keratinocytes (Kanda and Watanabe,
2005). CRH has also been shown to stimulate NF-kB in
HaCaT human keratinocytes (Zbytek et al, 2004), which may
then release cytokines or neuropeptides that could further
activate mast cells (Paus et al, in press). In addition to his-
tamine, which is well known to stimulate c-fibers, other
triggers and mediators may be involved in the itching as-
sociated with contact dermatitis and chronic urticaria. Mast
cells are known to be activated by neuropeptides, such as
substance P (SP), neurotensin (NT), and pituitary adenylate
cyclase activating polypeptide (PACAP) released from hu-
man dermal neurons (Theoharides et al, 2004).
The present findings suggest that CRH-R and mast cells
may participate in the pathogenesis of chronic urticaria,
especially when worsened by stress (Theoharides and Co-
chrane, 2004). Additional studies with more patients and
immunocytochemistry of affected lesions for CRH-R1 pro-
tein expression would be required to provide conclusive
evidence for CRH-R1 involvement.
Materials and Methods
Methods Expression of CRH-R1 and HDC was investigated using
real-time quantitative PCR in human skin samples (Table I) as fol-
lows: (a) two females and one male with chronic urticaria, (b) one
female with lichen simplex, (c) one male with lichen simplex, (d)
unaffected skin from one female with poikiloderma of unknown
origin, (e) unaffected skin from a mastectomy, (f) one normal infant
foreskin, as well as (g) human cultured keratinocytes (HaCaT).
All skin biopsies requiring two stitches were collected in Greece
for diagnostic purposes. The Medical Ethics Committee of Attikon
Hospital HIRB approved all described studies. All participants gave
their written informed concent according to the Declaration of
Helsinki Principles. All biopsy samples were obtained from patients
who had not received any medication for 15 d prior to biopsy;
these patients were free from any other medical problems, but
reported exacerbations of their skin symptoms by emotional
stress. The foreskin was obtained from the pediatric Urology Di-
vision of Tufts-New England Medical Center under Exemption 4
(discarded material without any identifying information). All biop-
sies were immediately placed in RNAlater solution (Ambion, Austin,
Texas) and stored at 201C.
HaCaT human keratinocytes were grown in Dulbecco’s Mod-
ified Eagle’s Medium (DMEM) with 10% fetal bovine serum (GIB-
CO, Grand Island, New York), plus 1% antibiotic/antimycotic
(GIBCO) solution (Slominski et al, 1998).
Total RNA extraction and cDNA synthesis Total RNA was ex-
tracted using the Qiagen RNeasy mini kit (Valencia, California) fol-
lowing the manufacturer’s specifications of RNA isolation from skin
tissue. Contaminating DNA was removed from all RNA prepara-
tions using Turbo DNase treatment (Ambion). RNA (500 ng) from
each sample was then used to perform first-strand cDNA synthesis
with 200 Units per mL Moloney Murine Leukemia Virus Reverse
Transcriptase (M-MLV RT), 50 pmol per mL random hexamer
oligonucleotide primer, 40 units per mL RNaseOUT recombinant
ribonuclease inhibitor (Invitrogen Life Technologies, Carlsbad, Cal-
ifornia) and 10 mM deoxynucleotide triphosphates (Roche Diag-
nostics, Mannheim, Germany). The reaction (20 mL) was run at
251C for 10 min, 371C for 50 min, and was inactivated by heating at
701C for 15 min.
Real-time quantitative PCR For real-time quantitative PCR am-
plification, the cDNA preparation was diluted 1:5 and 25 mL reac-
tion was prepared using the iTaq SYBR Green Supermix with ROX
(Bio-Rad Laboratories, Hercules, California) together with the
CRH-R1 (Sehringer et al, 2004) and HDC (Laszlo et al, 2001)
oligonucleotide primers. The CRH-R1 primers recognized all of the
R1, but not the R1g, isoforms that were recently reported to be
expressed both by human keratinocytes (Slominski et al, 2000b)
and mast cells (Cao et al, 2005). The specificity of the CRH-R1
PCR primers was tested under conventional PCR conditions, and
shown to amplify a single product of 66 bp length. Ribosomal RNA
control primers (18S) were used for endogenous control with the
same SYBR Green reaction cocktail. 100 nM of each primer was
used in the final reaction. PCR was carried out in a 7300 sequence
detector (Applied Biosystems, Foster City, California). Thermal
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Differential gene expression of
corticotropin-releasing hormone
receptor-1 and histidine dec-
arboxylase in human skin sam-
ples (n¼ 3) by real-time quanti-
tative PCR. Relative quantities were
normalized against 18S internal
control and results are expressed
as fold induction above mRNA ex-
pression in normal foreskin. TaqMan
runs were performed with cDNA
reverse transcribed from 50 ng
RNA from each sample. (po0.01,
po0.001). F, female; M, male.
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cycling proceeded at 951C for 15 s and 601C for 1 min, for 40
cycles. Input RNA amounts were normalized against 18S and the
control (foreskin) cDNA. Experiments were performed in quadru-
plicate for each data point.
Normal positive controls included foreskin, unaffected breast
skin as well as HaCaTcells that have both been previously reported
to express CRH-R1 (Slominski et al, 2000b). Negative controls in-
cluded; (a) sample without RT to control for genomic DNA con-
tamination which gave no product in regular RT-PCR amplification
for 30 cycles in our cDNA preparations, and (b) sample with water
instead of template to check for external contamination.
Statistics Results were normalized against an 18S internal control
and are expressed as induction over mRNA expression of normal
foreskin. Results are presented as mean  SD (n¼ 3) and were
analyzed using the two-tailed Student’s t test. Significance is de-
noted by po0.05.
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